Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07482930

Transcutaneous Auricular Vagus Nerve Stimulation and Spirometry: Sham-Controlled Randomized Trial

This study will examine the short-term effects of transcutaneous auricular vagus nerve stimulation (a non-invasive electrical stimulation delivered through the outer ear) on lung function measured by spirometry in healthy adults. The vagus nerve is involved in many automatic body functions, and ear-based stimulation has been used in research to explore its possible effects on different physiological systems. However, it is not clear whether a brief stimulation session can acutely influence breathing test results in people without respiratory disease.

Healthy volunteers aged 18-40 will take part in one laboratory visit. Participants will be randomly assigned to one of two groups: (1) active bilateral stimulation applied to specific ear regions that are known to be innervated by the vagus nerve, or (2) sham stimulation using the same device setup but designed to minimize vagal activation. The stimulation session will last approximately 10 minutes. Before and after the stimulation, participants will perform standard spirometry (breathing) tests. Primary spirometric outcomes will include common measures of lung function such as forced vital capacity (FVC), forced expiratory volume in one second (FEV1), and peak expiratory flow (PEF). Heart rate, heart rate variability, and blood pressure may also be recorded to monitor physiological responses and safety during the visit.

Participation is voluntary and participants may withdraw at any time. The procedure is considered minimal risk. Possible side effects are usually mild and temporary, such as tingling, warmth, or mild discomfort at the ear. Rarely, participants may feel lightheaded; if this occurs, the procedure will be stopped and the participant will be monitored until symptoms resolve. There is no guaranteed direct benefit to participants. The results may help clarify whether short-term ear-based vagus nerve stimulation can influence spirometric parameters and may inform future studies on autonomic and respiratory interactions.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Güzelyurt Neighborhood, Mustafa Bozkurt Street, No: 9, 57900, Türkeli, Sinop, Türkiye

Sinop, 57900, Turkey (Türkiye)

Location status: Recruiting

Location contact

Berkay Eren PEHLİVANOĞLU, MSc, PhD

SUB_INVESTIGATOR

Mesut ARSLAN, MSc, PhD

SUB_INVESTIGATOR

Uğur BAĞCI, PT, MSc

SUB_INVESTIGATOR

About this study

Transcutaneous auricular vagus nerve stimulation (taVNS) is a non-invasive neuromodulation approach delivered through the external ear. The auricular branch of the vagus nerve provides an accessible peripheral route that may influence autonomic regulation and, through autonomic-respiratory interactions, potentially affect respiratory function. Although taVNS has been investigated across several physiological domains, evidence regarding its acute effects on spirometric outcomes in healthy individuals remains limited. This study is designed to evaluate whether a single, brief session of bilateral taVNS produces measurable short-term changes in standard spirometric parameters compared with a sham procedure.

This is a sham-controlled, randomized, single-blind, parallel-group trial conducted in healthy volunteers. Participants are allocated to either active bilateral taVNS or sham stimulation using a predefined randomization procedure and concealed assignment. To minimize expectancy effects, participants are blinded to group allocation, and active and sham procedures use the same device appearance and session structure. Active stimulation is delivered via electrodes positioned on auricular regions targeted for vagal innervation, whereas sham stimulation uses an alternative placement intended to minimize vagal activation while maintaining a similar sensory experience. Stimulation parameters are standardized across participants, with intensity individually titrated to a clearly perceptible but non-painful level.

The primary outcomes are acute pre-to-post changes in spirometric measures obtained using standardized spirometry procedures. Key spirometric endpoints include forced vital capacity (FVC), forced expiratory volume in one second (FEV1), and peak expiratory flow (PEF). Secondary physiological measures may include heart rate, heart rate variability indices, and blood pressure to characterize autonomic and hemodynamic responses and to support safety monitoring during the session. All measurements are collected within the same visit, with spirometry performed immediately before and after the stimulation procedure following consistent instructions and quality criteria.

Data analysis will focus on between-group comparisons of change scores (post minus pre) for spirometric outcomes. Depending on distributional assumptions, analyses will use appropriate parametric or non-parametric methods; when relevant, models adjusting for baseline values will be applied (e.g., ANCOVA with baseline spirometry as a covariate). Effect sizes and confidence intervals will be reported to support interpretability. Safety will be monitored throughout the visit; stimulation will be discontinued if a participant experiences significant discomfort or requests stopping.

The study involves minimal risk. Expected adverse effects are transient and mild (e.g., localized tingling or mild discomfort at the ear). Rarely, lightheadedness may occur; participants will be monitored and the procedure stopped if necessary. Data will be stored in a coded/de-identified format and reported at the group level.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 18-40 years.
  • Healthy volunteers.
  • Able to perform spirometry and follow study instructions.
  • Provided written informed consent.

Exclusion criteria

  • Any cardiovascular disease, cardiac arrhythmia, hypertension, or related condition.
  • Any neurological disorder (e.g., diabetes mellitus, peripheral neuropathy, epilepsy).
  • Any diagnosed psychiatric disorder.
  • Any respiratory disease (e.g., asthma, chronic obstructive pulmonary disease).
  • Pregnancy or suspected pregnancy.
  • Ear conditions that prevent stimulation (infection, open wound, pain/tenderness) or presence of a piercing at/near the stimulation site.
  • Vigorous exercise within 24 hours prior to measurement.
  • Caffeine intake, smoking, or alcohol consumption within 4-6 hours prior to measurement.
  • Marked intolerance or hypersensitivity to the device or the procedure.
  • Inability to follow instructions during measurements or refusal to complete the session.

Treatment and study plan

Transcutaneous Auricular Vagus Nerve Stimulation

Device

Transcutaneous auricular vagus nerve stimulation is delivered bilaterally using an external stimulator with electrodes placed on auricular regions targeted for vagal innervation (e.g., cymba conchae). Stimulation is applied for approximately 10 minutes. Parameters are standardized (e.g., 25 Hz; pulse width 200-300 microseconds), and current intensity is individually adjusted to a clearly perceptible but non-painful level. The procedure is performed in a single visit with pre- and post-intervention spirometry and physiological monitoring as specified in the protocol.

Sham transcutaneous auricular stimulation

Device

Sham stimulation uses the same device, setup, and session duration to mimic the active procedure. Electrodes are placed on an ear location intended to minimize vagal activation (e.g., ear lobule), and stimulation is delivered at a minimal/low level to provide a similar sensation without therapeutic vagal stimulation. Pre- and post-session spirometry and other measurements are collected identically to the active arm.

Primary outcomes

  1. Change in forced expiratory volume in 1 second (FEV1)

    Time frame: Single visit: assessed pre-intervention and immediately post-intervention (within the same session).

    Forced expiratory volume in 1 second (FEV1), reported in liters (L), will be measured immediately before and immediately after the intervention. The outcome will be defined as the pre-to-post change (post minus pre), and between-group differences in change between active stimulation and sham control will be evaluated.[FVC], and peak expiratory flow [PEF]) will be measured immediately before and immediately after the intervention. The primary endpoint is the pre-to-post change (post minus pre) and the between-group difference in change between active stimulation and sham control.

  2. Change in forced vital capacity (FVC)

    Time frame: Single visit: assessed pre-intervention and immediately post-intervention (within the same session).

    Forced vital capacity (FVC), reported in liters (L), will be measured immediately before and immediately after the intervention. The outcome will be defined as the pre-to-post change (post minus pre), and between-group differences in change between active stimulation and sham control will be evaluated.

  3. Change in peak expiratory flow (PEF)

    Time frame: Single visit: assessed pre-intervention and immediately post-intervention (within the same session).

    Peak expiratory flow (PEF), reported in liters per minute (L/min), will be measured immediately before and immediately after the intervention. The outcome will be defined as the pre-to-post change (post minus pre), and between-group differences in change between active stimulation and sham control will be evaluated.

Secondary outcomes

  1. Change in RMSSD from chest recordings

    Time frame: Single visit: assessed pre-intervention and immediately post-intervention (within the same session).

    Heart rate variability will be recorded from chest-based beat-to-beat intervals before and after the intervention in a standardized resting condition. The root mean square of successive differences (RMSSD), reported in milliseconds (ms), will be derived from these recordings. The endpoint is the pre-to-post change (post minus pre) and the between-group difference in change between active bilateral stimulation and sham control.

  2. Change in SDNN from chest recordings

    Time frame: Single visit: assessed pre-intervention and immediately post-intervention (within the same session).

    Heart rate variability will be recorded from chest-based beat-to-beat intervals before and after the intervention in a standardized resting condition. The standard deviation of normal-to-normal intervals (SDNN), reported in milliseconds (ms), will be derived from these recordings. The endpoint is the pre-to-post change (post minus pre) and the between-group difference in change between active bilateral stimulation and sham control.

  3. Change in LF power from chest recordings

    Time frame: Single visit: assessed pre-intervention and immediately post-intervention (within the same session).

    Heart rate variability will be recorded from chest-based beat-to-beat intervals before and after the intervention in a standardized resting condition. Low-frequency (LF) power, reported in milliseconds squared (ms²), will be derived from these recordings. The endpoint is the pre-to-post change (post minus pre) and the between-group difference in change between active bilateral stimulation and sham control.

  4. Change in HF power from chest recordings

    Time frame: Single visit: assessed pre-intervention and immediately post-intervention (within the same session).

    Heart rate variability will be recorded from chest-based beat-to-beat intervals before and after the intervention in a standardized resting condition. High-frequency (HF) power, reported in milliseconds squared (ms²), will be derived from these recordings. The endpoint is the pre-to-post change (post minus pre) and the between-group difference in change between active bilateral stimulation and sham control.

  5. Change in LF/HF ratio from chest recordings

    Time frame: Single visit: assessed pre-intervention and immediately post-intervention (within the same session).

    Heart rate variability will be recorded from chest-based beat-to-beat intervals before and after the intervention in a standardized resting condition. The low-frequency/high-frequency (LF/HF) ratio, reported as a unitless measure, will be derived from these recordings. The endpoint is the pre-to-post change (post minus pre) and the between-group difference in change between active bilateral stimulation and sham control.

  6. Change in systolic blood pressure (SBP)

    Time frame: Single visit: assessed pre-intervention and immediately post-intervention (within the same session).

    Systolic blood pressure (SBP), reported in millimeters of mercury (mmHg), will be measured before and after the intervention under standardized conditions. The endpoint is the pre-to-post change (post minus pre) and the between-group difference in change between active stimulation and sham control.

  7. Change in diastolic blood pressure (DBP)

    Time frame: Single visit: assessed pre-intervention and immediately post-intervention (within the same session).

    Diastolic blood pressure (DBP), reported in millimeters of mercury (mmHg), will be measured before and after the intervention under standardized conditions. The endpoint is the pre-to-post change (post minus pre) and the between-group difference in change between active stimulation and sham control.

  8. Change in heart rate

    Time frame: Single visit: assessed pre-intervention and immediately post-intervention (within the same session).

    Heart rate, reported in beats per minute (bpm), will be measured before and after the intervention under standardized conditions. The endpoint is the pre-to-post change (post minus pre) and the between-group difference in change between active stimulation and sham control.

Study contacts

Contact information is provided by the study sponsor or research team.

SEFA HAKTAN HATIK, MSc, PhD

CONTACT

[email protected]

+90 368 271 55 28 ext. 4601

Sponsors and collaborators

Lead sponsor

SEFA HAKTAN HATIK

Other

Collaborators

  • Sinop University

Registry information

Official study title

Acute Effects Transcutaneous Auricular Vagus Nerve Stimulation on Spirometric Parameters in Healthy Individuals: A Sham-Controlled Randomized Study

Acronym: taVNS-SPIRO

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Mar 19, 2026
Registry last updated
Mar 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.